Application No. 09/242,772
Paper dated February 13, 2006
Response to Office Action dated December 29, 2005
Attorney Docket No. 0702-990278

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-52. (Canceled).

Claim 53. (Previously Presented) An isolated nucleic acid sequence consisting of 7313 base pairs as provided in SEQ ID NO. 116, with an open reading frame of 1500 base pairs starting with the ATG at position 481-483 as provided in SEQ ID NO. 116, wherein said open reading frame encodes for a pleomorphic adenoma gene 1 (PLAG1) protein.

Claim 54. (Currently Amended) An isolated hybrid nucleic acid sequence consisting of the isolated a nucleic acid sequence according to claim 53 fragment fused to a CTNNB1 translocation partner exons 3 to 5 of PLAG1 of claim 53, wherein said isolated hybrid nucleic acid sequence contains fragment consists of 509 base pairs corresponding to exon 1 of CTNNB1 fused to exons 3 to 5 of PLAG1, wherein said nucleic acid fragment is a CTNNB1 translocation partner of said PLAG1, and further wherein said isolated hybrid nucleic acid sequence allows the diagnosis of a cell containing said hybrid nucleic acid sequence as a tumor cell.

Claim 55. (Currently Amended) An isolated hybrid nucleic acid sequence consisting of the isolated a nucleic acid sequence according to claim 53 fragment fused to a CTNNB1 translocation partner exons 2 to 5 of PLAG1 of claim 53, wherein said isolated hybrid nucleic acid sequence contains fragment consists of 614 base pairs corresponding to exon 1 of CTNNB1 fused to exons 2 to 5 of PLAG1, wherein said nucleic acid fragment is a CTNNB1 translocation partner of said PLAG1, and further wherein said isolated hybrid nucleic acid sequence allows the diagnosis of a cell containing said hybrid nucleic acid sequence as a tumor cell.

Claim 56-58. (Canceled)